AARD - NASDAQ

Aardvark Therapeutics, Inc. Common Stock

AARD·NASDAQ

$3.81

-4.5%

HealthcareBiotechnology

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$83.12M

EPS-2.9300

P/E Ratio-1.30

Earnings Date08/12/2026

aard

Net Change in Cash

Last Annual Value

-14.59M

3-Year CAGR

-9%

5-Year CAGR

-5%

10-Year CAGR

-3%

Adjust for Inflation

Aardvark Therapeutics, Inc. Common Stock Competitors Analysis of Net Change in Cash

AARD · NASDAQ

Company	Net Change in Cash	CAGR 3Y	CAGR 5Y	CAGR 10Y
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD	-14.59M	N/A	N/A	N/A
Avalo Therapeutics, Inc. NASDAQ:AVTX	-118.59M	N/A	N/A	N/A
Aldeyra Therapeutics, Inc. NASDAQ:ALDX	15514.16B	N/A	904.2%	N/A
Annexon, Inc. NASDAQ:ANNX	112.55M	9.8%	N/A	N/A
Candel Therapeutics, Inc. NASDAQ:CADL	17.23M	N/A	-18.4%	N/A
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	53.66M	75.3%	N/A	N/A
Editas Medicine, Inc. NASDAQ:EDIT	13.90M	N/A	-26.3%	-10.5%
Galectin Therapeutics Inc. NASDAQ:GALT	2.60M	-28.3%	-27.0%	N/A
Assembly Biosciences, Inc. NASDAQ:ASMB	20.11M	N/A	N/A	29.9%
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA	-5.54M	N/A	N/A	N/A
Nautilus Biotechnology, Inc. NASDAQ:NAUT	-15.26M	N/A	N/A	N/A

Aardvark Therapeutics, Inc. Common Stock Fair Value Envelope

AARD · NASDAQ

Our analysis suggests that AARD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.81, this represents a potential HIDDEN relative to our calculated worth for Aardvark Therapeutics, Inc. Common Stock.

HIDDEN

Intrinsic Value

Current Price: $3.81

Related Guides

Blog Categories

Continue your AARD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.